{"id":"W4410813020","doi":"10.1200/jco.2025.43.16_suppl.5561","title":"Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Internal medicine; Clinical trial; Poly ADP ribose polymerase; Cancer; Cancer research; Gynecology; Genetics; DNA; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001323445,0.0009485661,0.000918727,0.0002752857,0.0002212706,0.0008847855,0.0007613436,0.001355396,0.007341669],"category_scores_gemma":[0.0009945589,0.0004478676,0.0008536819,0.0002888878,0.0007132429,0.0007694722,0.0005510934,0.002614359,0.001359983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000541163,"about_ca_system_score_gemma":0.001000093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004421906,"about_ca_topic_score_gemma":0.001412039,"domain_scores_codex":[0.99965,0.0001835732,0.00001228415,0.00006612854,0.00003069338,0.00005724204],"domain_scores_gemma":[0.9995284,0.00008759928,0.0001031966,0.00006313343,0.00003034614,0.0001872977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6355545,0.04998425,0.01136615,0.001736816,0.0007759809,0.000302072,0.0005470606,0.005276308,0.05991037,0.001118392,0.01593473,0.2174934],"study_design_scores_gemma":[0.5516655,0.4114571,0.0155099,0.00009735193,0.0002508214,0.0007104284,0.0001098525,0.002228206,0.004602906,0.0007162045,0.01260576,0.00004596072],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.971347,0.003294163,0.001562428,0.001393037,0.0002142212,0.008800555,0.004761009,0.0004475784,0.008179966],"genre_scores_gemma":[0.9655961,0.001664871,0.004814473,0.002366497,0.0001711898,0.008655034,0.00763995,0.0001230011,0.008968906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007341669,"threshold_uncertainty_score":0.02456039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1042435243421501,"score_gpt":0.5265013115800238,"score_spread":0.4222577872378737,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}